Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Jan Basile

Showing results (71-80 of 78) with videos related to

Pageof 8
Sort By:
You have reached the last page of results.This site can display upto 78 results.
The Journal of Clinical Endocrinology and Metabolism|April 21, 2022
Novel Indices of Cognitive Impairment and Incident Cardiovascular Outcomes in the REWIND TrialTali Cukierman-Yaffe, Hertzel C Gerstein, Jan Basile, et al.
The Lancet. Neurology|June 21, 2020
Effect of dulaglutide on cognitive impairment in type 2 diabetes: an exploratory analysis of the REWIND trialTali Cukierman-Yaffe, Hertzel C Gerstein, Helen M Colhoun, et al.
Lancet (London, England)|May 19, 2021
Ultrasound renal denervation for hypertension resistant to a triple medication pill (RADIANCE-HTN TRIO): a randomised, multicentre, single-blind, sham-controlled trialMichel Azizi, Kintur Sanghvi, Manish Saxena, et al.
The Lancet. Diabetes & Endocrinology|January 12, 2020
The effect of dulaglutide on stroke: an exploratory analysis of the REWIND trialHertzel C Gerstein, Robert Hart, Helen M Colhoun, et al.
Diabetes, Obesity & Metabolism|June 3, 2017
Design and baseline characteristics of participants in the Researching cardiovascular Events with a Weekly INcretin in Diabetes (REWIND) trial on the cardiovascular effects of dulaglutideHertzel C Gerstein, Helen M Colhoun, Gilles R Dagenais, et al.
Journal of the American Society of Nephrology : JASN|June 24, 2017
Effects of Intensive BP Control in CKDAlfred K Cheung, Mahboob Rahman, David M Reboussin, et al.
Lancet (London, England)|June 14, 2019
Dulaglutide and renal outcomes in type 2 diabetes: an exploratory analysis of the REWIND randomised, placebo-controlled trialHertzel C Gerstein, Helen M Colhoun, Gilles R Dagenais, et al.
Lancet (London, England)|June 14, 2019
Dulaglutide and cardiovascular outcomes in type 2 diabetes (REWIND): a double-blind, randomised placebo-controlled trialHertzel C Gerstein, Helen M Colhoun, Gilles R Dagenais, et al.
Pageof 8

Showing results (71-80 of 78) with videos related to

Sort By:
Pageof 8
You have reached the last page of results.This site can display upto 78 results.
The Journal of Clinical Endocrinology and Metabolism|April 21, 2022
Novel Indices of Cognitive Impairment and Incident Cardiovascular Outcomes in the REWIND TrialTali Cukierman-Yaffe, Hertzel C Gerstein, Jan Basile, et al.
The Lancet. Neurology|June 21, 2020
Effect of dulaglutide on cognitive impairment in type 2 diabetes: an exploratory analysis of the REWIND trialTali Cukierman-Yaffe, Hertzel C Gerstein, Helen M Colhoun, et al.
Lancet (London, England)|May 19, 2021
Ultrasound renal denervation for hypertension resistant to a triple medication pill (RADIANCE-HTN TRIO): a randomised, multicentre, single-blind, sham-controlled trialMichel Azizi, Kintur Sanghvi, Manish Saxena, et al.
The Lancet. Diabetes & Endocrinology|January 12, 2020
The effect of dulaglutide on stroke: an exploratory analysis of the REWIND trialHertzel C Gerstein, Robert Hart, Helen M Colhoun, et al.
Diabetes, Obesity & Metabolism|June 3, 2017
Design and baseline characteristics of participants in the Researching cardiovascular Events with a Weekly INcretin in Diabetes (REWIND) trial on the cardiovascular effects of dulaglutideHertzel C Gerstein, Helen M Colhoun, Gilles R Dagenais, et al.
Journal of the American Society of Nephrology : JASN|June 24, 2017
Effects of Intensive BP Control in CKDAlfred K Cheung, Mahboob Rahman, David M Reboussin, et al.
Lancet (London, England)|June 14, 2019
Dulaglutide and renal outcomes in type 2 diabetes: an exploratory analysis of the REWIND randomised, placebo-controlled trialHertzel C Gerstein, Helen M Colhoun, Gilles R Dagenais, et al.
Lancet (London, England)|June 14, 2019
Dulaglutide and cardiovascular outcomes in type 2 diabetes (REWIND): a double-blind, randomised placebo-controlled trialHertzel C Gerstein, Helen M Colhoun, Gilles R Dagenais, et al.
Pageof 8